March 14, 2017
Private companies AMO Pharma, Renedis Pharmaceutical team up to develop RND-001 for rare genetic diseases
AMO Pharma Limited and Ranedis Pharmaceuticals,two privately held U.S. pharma companies have partnered up to develop RND-001 for rare genetic diseases, including certain lysosomal storage disorders and other diseases affecting the central nervous system.